UA95951C2 - Recombinant attenuated clostridium organisms - Google Patents

Recombinant attenuated clostridium organisms

Info

Publication number
UA95951C2
UA95951C2 UAA200813301A UAA200813301A UA95951C2 UA 95951 C2 UA95951 C2 UA 95951C2 UA A200813301 A UAA200813301 A UA A200813301A UA A200813301 A UAA200813301 A UA A200813301A UA 95951 C2 UA95951 C2 UA 95951C2
Authority
UA
Ukraine
Prior art keywords
recombinant attenuated
attenuated clostridium
clostridium organisms
organisms
recombinant
Prior art date
Application number
UAA200813301A
Other languages
English (en)
Ukrainian (uk)
Inventor
Марк Д. Кочран
Гари Петерсен
Стивен В. Лер
Ричард СИНЕНКИ
Original Assignee
Шеринг-Плау Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг-Плау Лтд. filed Critical Шеринг-Плау Лтд.
Publication of UA95951C2 publication Critical patent/UA95951C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)

Abstract

Изобретение относится к аттенуированным организмам, которые экспрессируют главным образом нетоксичный альфа-токсин. Экспрессированный альфа-токсин представляет собой делетированный мутант, у которого, по сравнению с альфа-токсином зрелого штамма 13 альфа-токсина, отсутствуют по меньшей мере девять последовательных аминокислотных остатков, включая His.
UAA200813301A 2006-04-17 2007-12-04 Recombinant attenuated clostridium organisms UA95951C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79255306P 2006-04-17 2006-04-17

Publications (1)

Publication Number Publication Date
UA95951C2 true UA95951C2 (en) 2011-09-26

Family

ID=38625523

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201106572A UA109105C2 (uk) 2006-04-17 2007-04-12 Молекула нуклеїнової кислоти, що кодує істотно нетоксичний мутеїн альфа-токсину clostridium perfringens, та істотно нетоксичний мутеїн альфа-токсину clostridium perfringens
UAA200813301A UA95951C2 (en) 2006-04-17 2007-12-04 Recombinant attenuated clostridium organisms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201106572A UA109105C2 (uk) 2006-04-17 2007-04-12 Молекула нуклеїнової кислоти, що кодує істотно нетоксичний мутеїн альфа-токсину clostridium perfringens, та істотно нетоксичний мутеїн альфа-токсину clostridium perfringens

Country Status (24)

Country Link
US (3) US7732187B2 (ru)
EP (2) EP2368571A1 (ru)
JP (2) JP5551933B2 (ru)
KR (1) KR20080110908A (ru)
CN (1) CN101489584B (ru)
AR (2) AR060471A1 (ru)
AU (1) AU2007240949B2 (ru)
BR (1) BRPI0711572A2 (ru)
CA (1) CA2649426C (ru)
CO (1) CO6140037A2 (ru)
EC (1) ECSP088827A (ru)
ES (1) ES2401810T3 (ru)
HK (1) HK1125315A1 (ru)
IL (1) IL194714A (ru)
MX (1) MX2008013451A (ru)
NO (1) NO20084810L (ru)
NZ (1) NZ571970A (ru)
PE (1) PE20080167A1 (ru)
PL (1) PL2007420T3 (ru)
RU (2) RU2593945C2 (ru)
TW (1) TWI338045B (ru)
UA (2) UA109105C2 (ru)
WO (1) WO2007123850A2 (ru)
ZA (1) ZA200808872B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2009134891A2 (en) * 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
WO2012033814A2 (en) * 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
EA035513B1 (ru) 2011-07-22 2020-06-29 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" ВАКЦИНА, СОДЕРЖАЩАЯ БЕЛОК Als3, ДЛЯ ЛЕЧЕНИЯ У МЛЕКОПИТАЮЩЕГО АБСЦЕССА КОЖИ, ОБУСЛОВЛЕННОГО STAPHYLOCOCCUS AUREUS
TWI592422B (zh) * 2012-03-02 2017-07-21 再生元醫藥公司 抗艱難梭狀芽孢桿菌毒素之人類抗體
EP2911688B1 (en) 2012-10-26 2019-10-16 Intervet International B.V. Cross-protecting salmonella vaccines
EA030005B1 (ru) 2013-03-15 2018-06-29 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN109602898B (zh) * 2018-12-28 2022-02-22 江苏省农业科学院 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114621963A (zh) * 2022-03-11 2022-06-14 牧原食品股份有限公司 一种猪魏氏梭菌a型的亚单位疫苗及其制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1483042A (en) 1974-07-29 1977-08-17 Lapointe J Anti-tumour product of bacterial origin
SU627612A1 (ru) 1977-09-30 1980-02-05 Zemlyakova V P Препарат земл ковой в.п. против клюстридиозов животных и птиц
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
NZ253189A (en) 1992-05-20 1996-08-27 Secr Defence Peptides comprising amino acid sequences of clostridium perfringens alpha toxins, vaccines containing them, antibodies and their use
GB9605222D0 (en) 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines
PT892054E (pt) * 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
RU2129441C1 (ru) * 1997-12-10 1999-04-27 Пирожков Михаил Константинович Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US6908620B2 (en) * 2002-12-09 2005-06-21 University Of Georgia Research Foundation, Inc. Coccidial vaccine and methods of making and using same
CN102861325A (zh) * 2003-11-10 2013-01-09 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
MY149604A (en) 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine

Also Published As

Publication number Publication date
BRPI0711572A2 (pt) 2011-11-16
HK1125315A1 (en) 2009-08-07
EP2007420B1 (en) 2013-03-06
CA2649426C (en) 2014-04-01
ES2401810T3 (es) 2013-04-24
PL2007420T3 (pl) 2013-08-30
CN101489584A (zh) 2009-07-22
CA2649426A1 (en) 2007-11-01
US20110008389A1 (en) 2011-01-13
US20070286874A1 (en) 2007-12-13
AR060471A1 (es) 2008-06-18
CO6140037A2 (es) 2010-03-19
ECSP088827A (es) 2008-11-27
JP5551933B2 (ja) 2014-07-16
TWI338045B (en) 2011-03-01
CN101489584B (zh) 2013-05-01
ZA200808872B (en) 2009-11-25
NZ571970A (en) 2012-02-24
WO2007123850A3 (en) 2008-03-06
AR079941A2 (es) 2012-02-29
TW200801182A (en) 2008-01-01
IL194714A0 (en) 2011-08-01
AU2007240949B2 (en) 2013-03-14
AU2007240949A1 (en) 2007-11-01
US7807456B2 (en) 2010-10-05
RU2011147308A (ru) 2013-05-27
JP2009533071A (ja) 2009-09-17
MX2008013451A (es) 2008-10-30
RU2593945C2 (ru) 2016-08-10
NO20084810L (no) 2009-01-16
IL194714A (en) 2015-03-31
EP2007420A2 (en) 2008-12-31
US7972604B2 (en) 2011-07-05
RU2008144913A (ru) 2010-05-27
KR20080110908A (ko) 2008-12-19
US7732187B2 (en) 2010-06-08
RU2445364C2 (ru) 2012-03-20
UA109105C2 (uk) 2015-07-27
PE20080167A1 (es) 2008-03-10
JP2013255518A (ja) 2013-12-26
US20100166800A1 (en) 2010-07-01
EP2368571A1 (en) 2011-09-28
WO2007123850A2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
UA95951C2 (en) Recombinant attenuated clostridium organisms
NZ594457A (en) Compositions and methods for the delivery of oxygen
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
WO2008153776A8 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions
MX337147B (es) Composiciones y metodos para utilizar peptidos proislet y sus analogos.
ZA201001054B (en) Peptide with reduced dimer formation
MX336737B (es) Composiciones y metodos que comprenden variantes de proteasa serina.
PH12018502465A1 (en) Mic-1 compounds and use thereof
UA102506C2 (ru) Селективные аналоги глюкагоноподобного пептида-2 (glp-2)
EP2455460A3 (en) Lipase variants for pharmaceutical use
CA2651990C (en) Improved antimicrobial peptides
PH12019550241A1 (en) Mic-1 compounds and uses thereof
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
MX2008009493A (es) Peptido novedoso y uso del mismo.
NZ743910A (en) Purification of iduronate-2-sulfatase
MY160995A (en) Polypeptides with permease activity
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
HRP20030876B1 (en) Photosensitiser and method for production thereof
TW200732417A (en) Composition containing polylactic acid
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
WO2007083100A3 (en) Enzyme
MX2010008668A (es) Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona.
MX2011007736A (es) Compuestos de hormona del crecimiento estables.
MX2009005117A (es) Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.
ITRM20050064A1 (it) Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.